The effect of granulocyte and monocyte adsorptive apheresis on serum cytokine levels in patients with ulcerative colitis

Cytokine

Volumn 62, Issue 1, 2013, Pages 146-150

  Toya, Yosuke ^a   Chiba, Toshimi ^a   Mizutani, Tomomi ^a   Sato, Kunihiko ^a   Kasugai, Satoshi ^a   Matsuda, Nozomi ^a   Orikasa, Shunsuke ^a   Shibata, Sho ^a   Abiko, Yukito ^a   Akasaka, Risaburo ^a   Yokoyama, Naoki ^a   Oana, Shuhei ^a   Hirota, Shigeru ^a   Endo, Masaki ^a   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Cytokine levels; GMA; Granulocyte and monocyte adsorptive apheresis; Interleukin 10; Ulcerative colitis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APHERESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; FEMALE; FLOW RATE; GRANULOCYTE AND MONOCYTE ADSORPTIVE APHERESIS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERAPY EFFECT; TREATMENT DURATION; ULCERATIVE COLITIS;

ADSORPTION; ADULT; BLOOD COMPONENT REMOVAL; COLITIS, ULCERATIVE; CYTOKINES; FEMALE; GRANULOCYTES; HUMANS; INTERLEUKIN-10; MALE; MONOCYTES;

EID: 84875809977     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.01.019     Document Type: Article

References (30)

1. Selby W., Janossy G., Bofil M., Jewell D.P. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistochemical and cell isolation techniques. Gut 1984, 25:32-40.
2. Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M.K., Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119:15-22.
3. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
4. Hanai H., Watanabe F., Saniabadi A.R., Matsushitai I., Takeuchi K., Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig. Dis. Sci. 2002, 47:2349-2353.
5. Nikolaus S., Bauditz J., Glonchetti P., Witt C., Lochs H., Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998, 42:470-476.
6. Cassatella M.A. The production of cytokines by polymorphonuclear neutrophils. Immunol. Today 1995, 16:21-26.
7. Edwards S.W., Hallett M.B. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol. Today 1997, 18:320-324.
8. Akira S. The role of IL-18 in innate immunity. Curr. Opin. Immunol. 2000, 12:59-63.
9. Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378:88-91.
10. Lim W.C., Hanauer S.B. Emerging biologic therapies in inflammatory bowel disease. Gastroenterol. Disord. 2004, 4:66-85.
11. Saniabadi A.R., Hanai H., Fukunaga K., Sawada K., Shima C., Bjarnason I., et al. Therapeutic leucocytapheresis for inflammatory bowel disease. Transfus. Apheresis Sci. 2007, 37:191-200.
12. Saniabadi A.R., Hanai H., Suzuki Y., Ohmori T., Sawada K., Yoshimura N., et al. Adacolumn for selective leucocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?. J. Clin. Apheresis 2005, 20:171-184.
13. Saniabadi A.R., Hanai H., Takeuchi K., Umemura K., Nakashima M., Adachi T., et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther. Apheresis Dial. 2003, 7:48-59.
14. Hanai H., Watanabe F. Takeuchi k, et al. Leucocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin. Gastroenterol. Hepatol. 2003, 1:28-35.
15. Suzuki Y., Yoshimura N., Saniabadi A.R., Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig. Dis. Sci. 2004, 49:565-571.
16. Hanai H., Watanabe F., Takeuchi K., Iida T., Yamada M., Iwaoka Y., et al. Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J. Gastroenterol. 2006, 12:3393-3399.
17. Shimoyama T., Sawada K., Hiwatashi N., Sawada T., Matsueda K., Munakata A., et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J. Clin. Apheresis 2001, 16:1-9.
18. Fukuda Y., Matsui T., Suzuki Y., Kanke K., Matsumoto T., Takazoe M., et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J. Gastroenterol. 2004, 39:1158-1164.
19. Naganuma M., Funakoshi S., Sakuraba A., Takagi H., Inoue N., Ogata H., et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or dependent ulcerative colitis. Inflamm. Bowel Dis. 2004, 10:251-257.
20. Vignali D.A. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 2000, 243:243-255.
21. Bouma G., Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 2003, 3:521-533.
22. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204:1849-1861.
23. ++ monocytes in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2008, 103:1210-1216.
24. Iwakami Y., Sakuraba A., Sato T., Takada Y., Izumiya M., Ichikawa H., et al. Granulocyte and monocyte adsorption apheresis therapy modulates monocyte-derived dendritic cell function in patients with ulcerative colitis. Ther. Apheresis Dial. 2009, 13:138-146.
25. Aoki H., Nakamura K., Yoshimatsu Y., Tsuda Y., Irie M., Fukuda K., et al. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig. Dis. Sci. 2007, 52:1427-1433.
26. Noguchi A., Watanabe K., Narumi S., Yamagami H., Fujiwara Y., Higuchi K., et al. The production of interferon-γ-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol 2007, 42:947-956.
27. Cuadrado E., Alonso M., de Juan M.D., Echaniz P., Arenas J.I. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis. World J. Gastroenterol. 2008, 14:1521-1527.
28. Chiba T., Endo M., Matsushita S., Sasaki M., Chida S., Toya Y., et al. Peripheral blood CD64 levels decrease in Crohn's disease following granulocyte and monocyte adsorptive apheresis. Case Rep. Gastroenterol. 2011, 5:667-671.
29. Nagase K., Fukunaga K., Kashiwamura S., Kono T., Kamikozuru K., Yokoyama Y., et al. Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn's disease. Ther. Apheresis Dial. 2011, 15:367-373.
30. Grimm M.C., Doe W.F. Chemokines in IBD mucosa: expression of RANTES, MIP-1α, MIP-1β and interferon inducible protein 10 by macrophages, lymphocytes, endothelial cells and granulomas. Inflamm. Bowel Dis. 1996, 2:88-96.